Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in Australian primary care patients: only part of the story?
Orji, Nneka, Campbell, Julie A, Wills, Karen et al. · BMC public health · 2022 · DOI
Quick Summary
This study looked at how many people in Australia have ME/CFS by examining medical records from primary care clinics between 2015-2019. Researchers found that roughly 95-104 people per 100,000 have ME/CFS in Australia, but they also discovered that many patients avoid visiting their doctors because of stigma, disbelief in the condition, and lack of available treatments. The researchers concluded that the real number of people with ME/CFS is likely much higher than what their numbers show.
Why It Matters
This study provides the first Australian prevalence estimates for ME/CFS in primary care, establishing that ME/CFS affects a substantial population often overlooked in health policy and resource allocation. The qualitative findings expose critical barriers to diagnosis and care—including medical disbelief and stigma—which directly impact patient access to recognition and support, informing advocacy and health system reform efforts.
Observed Findings
Crude ME/CFS prevalence in Australian primary care ranged from 94.9-103.9 per 100,000 population across 2015-2019.
Female prevalence was approximately 2.3-2.8 times higher than male prevalence (130.0-141.4/100,000 vs 50.9-57.5/100,000).
Highest prevalence occurred in age groups 40-49 and 50-59 years.
Qualitative interviews identified diagnostic barriers including lack of recognition by healthcare providers, absence of effective treatments, stigma, and disbelief in ME/CFS as a legitimate condition.
Patients reported limited primary care engagement due to perceived futility of seeking care and medical skepticism.
Inferred Conclusions
ME/CFS affects a substantial but underestimated number of Australians; reported primary care prevalence (approximately 20,000-22,000 people) likely represents only a fraction of true disease burden.
Systemic barriers—diagnostic delays, provider disbelief, stigma, and treatment scarcity—prevent many people with ME/CFS from being recognized in primary care and engaging with healthcare systems.
Robust community-based case ascertainment using validated criteria is essential for accurate prevalence estimation and informing health policy and resource allocation.
Remaining Questions
What is the true prevalence of ME/CFS in the Australian community when using standardized case definitions in population-based (not primary care-limited) samples?
What This Study Does Not Prove
This study does not establish the true prevalence of ME/CFS in the Australian community, as it only captures diagnosed cases in primary care among regular attendees; patients with undiagnosed ME/CFS or those who avoid healthcare are systematically excluded. The study cannot determine causation for why certain demographics (females, ages 40-59) have higher recorded prevalence, nor can it prove that the observed barriers fully account for underdiagnosis. The findings reflect primary care practices specifically and may not generalize to specialist or secondary care settings.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
How do diagnostic and care-seeking barriers differ between Australia's various healthcare regions and socioeconomic groups, and what interventions could address them?
What proportion of Australians with ME/CFS remain entirely undiagnosed in both primary and secondary care settings?
How does the disease burden and health economic impact of ME/CFS compare to other chronic conditions in Australia's health policy priority ranking?